0000000000224917

AUTHOR

Mustafa Cesur

showing 10 related works from this author

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

2022

The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for th…

LipoproteinsEndocrinology Diabetes and MetabolismDiabetes030209 endocrinology & metabolism030204 cardiovascular system & hematologyCardiovascular riskAtherosclerosisIncretinsBiochemistrySmall dense LDL3. Good health03 medical and health sciences0302 clinical medicineAtherosclerosis Cardiovascular risk Diabetes GLP-1 Incretins Lipoproteins Small dense LDL Therapylipids (amino acids peptides and proteins)TherapyGLP-1Molecular BiologyMetabolites
researchProduct

The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO I…

2022

Coronavirus disease 2019 (COVID-19) is a highly heterogeneous disease regarding severity, vulnerability to infection due to comorbidities, and treatment approaches. The hypothalamic–pituitary–adrenal (HPA) axis has been identified as one of the most critical endocrine targets of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that might significantly impact outcomes after infection. Herein we review the rationale for glucocorticoid use in the setting of COVID-19 and emphasize the need to have a low index of suspicion for glucocorticoid-induced adrenal insufficiency, adjusting for the glucocorticoid formulation used, dose, treatment duration, and underlying health problems. We a…

Hypothalamo-Hypophyseal SystemHydrocortisoneSARS-CoV-2Organic ChemistryCOVID-19Pituitary-Adrenal SystemGeneral MedicineCatalysisComputer Science ApplicationsInorganic ChemistrySARS-CoV-2 adrenal insufficiency glucocorticoids hypercortisolism hypothalamic–pituitary–adrenal axisHumansPhysical and Theoretical ChemistryMolecular BiologyGlucocorticoidsSpectroscopyInternational journal of molecular sciences
researchProduct

Critical questions in diabetes management: What are the most compelling challenges and how can we handle them?

2022

Background: The prevalence of diabetes mellitus is growing worldwide, showing almost a 10-fold increase in the last five decades. Despite advances in the understanding of the disease mechanisms, preventive measures, and treatment options, morbidity and mortality remain high. Moreover, the burden of uncontrolled glycemia and associated complications have a significant impact on healthcare costs. To be ready for the future and emerging issues in the management of diabetes and related disorders, a holistic approach is essential for the prevention of the next generations. So many challenges in the management of diabetes exist globally, which differ according to the health infrastructure, and cu…

Internal MedicineDiabetes treatment Diabetogenic environment Health literacy InertiaCardiology and Cardiovascular MedicineInternational Journal of Cardiology Cardiovascular Risk and Prevention
researchProduct

Prevalence of dyslipidemia and associated risk factors in Turkish adults.

2013

Background and Objectives Dyslipidemia is a modifiable major risk factor for coronary heart disease. The objective of this study was to determine the prevalence of dyslipidemia among Turkish adults and its associations with other cardiovascular risk factors. Methods This study included 4309 people ages 20 to 83 years old from 7 provinces of Turkey. People from the city centers, districts, and villages were selected by a stratified sampling method. Weight, height, and waist and hip circumferences were measured. Blood samples were obtained to determine glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides …

AdultMalemedicine.medical_specialtyWaistTurkeygenetic structuresEndocrinology Diabetes and MetabolismCoronary DiseaseBody Mass Indexchemistry.chemical_compoundHigh-density lipoproteinCholesterol Dyslipidemia High-density lipoprotein Low-density lipoprotein Prevalence Triglycerides TurkeyRisk FactorsInternal medicinePrevalenceInternal MedicinemedicineHumansRisk factorNational Cholesterol Education ProgramTriglyceridesAgedDyslipidemiasAged 80 and overNutrition and Dieteticsbusiness.industryCholesterolBody WeightCholesterol HDLnutritional and metabolic diseasesCholesterol LDLMiddle Agedmedicine.diseaseCholesterolBlood pressurechemistryPhysical therapyFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessBody mass indexDyslipidemia
researchProduct

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

2009

Abstract Objective : Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. Design and Methods We identified 25 subjects with RA (47±8 years, body mass index (BMI) 25±4kg/m 2 ) by the American College of Rheumatology diagnostic criteria, with a disease durations Results As compared to controls RA patients had higher plasma triglycerides (1.8±0.5 vs. 1.0±0.5mmol/L, p p =0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lo…

medicine.medical_specialtyCholesterolbusiness.industry10265 Clinic for Endocrinology and DiabetologyArthritisBlood lipids610 Medicine & healthRheumatoid arthritis small dense LDL HDL-cholesterol Triglyceridesmedicine.disease2705 Cardiology and Cardiovascular MedicineRheumatologychemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineRheumatoid arthritisLow-density lipoproteinmedicineCardiology and Cardiovascular MedicinebusinessaterosclerosiDyslipidemia
researchProduct

An update on the relationships between rheumatoid arthritis and atherosclerosis

2010

Rheumatoid arthritis is a chronic inflammatory disease. Cardiovascular events are the most important cause of mortality and morbidity in patients with rheumatoid arthritis. Beyond the traditional cardiovascular risk factors, chronic systemic inflammation has been shown to be a crucial factor in atherosclerosis development and progression from endothelial dysfunction to plaque rupture and thrombosis. Many studies have shown that atherosclerosis is not a passive event like accumulation of lipids in the vessel walls; by contrast, it represents an active inflammation of the vessels. Inflammatory cells such as macrophages, monocytes and T cells play important roles in the development of both rhe…

musculoskeletal diseasesT-LymphocytesAtherosclerosis Rheumatoid arthritis Inflammation Cardiovascular risk10265 Clinic for Endocrinology and DiabetologyInflammation610 Medicine & healthComorbiditySystemic inflammationModels BiologicalMonocytes2705 Cardiology and Cardiovascular MedicineArthritis RheumatoidRisk FactorsImmunopathologymedicineHumansEndothelial dysfunctionAutoimmune diseaseInflammationbusiness.industryVascular diseaseMacrophagesmedicine.diseaseAtherosclerosisThrombosisOxidative StressCardiovascular DiseasesRheumatoid arthritisImmunologyDisease Progressionmedicine.symptomInsulin ResistanceCardiology and Cardiovascular Medicinebusiness
researchProduct

Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.

2014

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiometabolic risk. Although dyslipidemia represents a key factor in this disease, its impact on serum levels of distinct lipoprotein subfractions is largely unknown.OBJECTIVE: To assess the full low-density lipoprotein (LDL) and high-density lipoprotein (I-EDL) profiles in patients with NAFLD.METHODS: Seven LDL and 10 HDL subfractions were assessed by gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA) in men with biopsy proven NAFLD (simple steatosis [n = 17, age, 34 7 years] and nonalcoholic steatohepatitis [NASH; n = 24, age, 32 +/- 6 years]). Exclusion criteria included robust alcohol consump…

AdultMalemedicine.medical_specialtySimple steatosiEndocrinology Diabetes and MetabolismBody Mass Indexchemistry.chemical_compoundHigh-density lipoproteinInsulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineInternal MedicineNutrition and DieteticNonalcoholic fatty liver diseaseHumansAspartate AminotransferasesLipoproteinNutrition and Dieteticsbiologybusiness.industryRisk FactorMedicine (all)Fatty livernutritional and metabolic diseasesAspartate AminotransferaseAlanine TransaminaseLipidMiddle Agedmedicine.diseaseAtherosclerosisFatty LiverLipoproteins LDLEndocrinologyAlanine transaminasechemistryAtherosclerosibiology.proteinFemaleNonalcoholic steatohepatitibusinessCardiology and Cardiovascular MedicineLipoproteins HDLBody mass indexDyslipidemiaLipoproteinHumanJournal of clinical lipidology
researchProduct

Post-COVID syndrome, inflammation, and diabetes

2022

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It i…

InflammationEndocrinologyCOVID-19 Long COVID New-onset diabetes Newly diagnosed diabetes Post-COVID syndrome SARS CoV-2 Syndemia Type 2 diabetesSARS-CoV-2Endocrinology Diabetes and MetabolismHyperglycemiaInternal MedicineDiabetes MellitusHumansCOVID-19RNA ViralPandemics
researchProduct

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health

2022

Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the…

Interleukin-6SARS-CoV-2Interleukin-8COVID-19COVID Cardiometabolic Diabetes Inflammation MolecularInterleukin-10Interferon-gammaAdipokinesDiabetes Mellitus Type 2Cardiovascular DiseasesCytokinesHumansInterleukin-2RNA ViralMolecular MedicineInterleukin-4ObesityPandemicsMolecular BiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

2022

: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been shown to disrupt many organ systems in the human body. Though several medical disorders have been affected by this infection, a few illnesses in addition may also play a role in determining the outcome of COVID-19. Obesity is one such disease which is not only affected by the occurrence of COVID-19 but can also result in a worse clinical outcome of COVID-19 infection. This manuscript summarizes the most recent evidence supporting the bidirectional impact of COVID-19 and obesity. It highlights how the presence of obesity can be detrimental to the outcome of COVID-19 in a given …

Syndemic.SARS-CoV-2Endocrinology Diabetes and MetabolismInternal MedicineBidirectional impactCOVID-19Obesity
researchProduct